Skip to main content
. 2020 Sep 17;11(9):1082. doi: 10.3390/genes11091082

Figure 1.

Figure 1

Expression level of CGB1 in cancer, according to The Cancer Genome Atlas (TCGA) data; TPM—transcripts per million; ACC—Adrenocortical carcinoma; BLCA—Bladder urothelial carcinoma; BRCA—Breast invasive carcinoma; CESC—Cervical squamous cell carcinoma; CHOL—Cholangiocarcinoma; COAD—Colon adenocarcinoma; DLBC—Lymphiod neoplasm diffuse large B-cell lymphoma; ESCA—Esophageal carcinoma; GBM—Glioblastoma multiforme; HNSC—Head and Neck squamous cell carcinoma; KICH—Kidney chromophobe; KIRC—Kidney renal clear cell carcinoma; KIRP—Kidney renal papillary cell carcinoma; LGG—Brain lower grade glioma; OV—Ovarian serous cystadenocarcinoma; MESO—Mesothelioma; LIHC—Liver hepatocellular carcinoma; LUAD—Lung adenocarcinoma; LUSC—Lung squamous cell carcinoma; PAAD—Pancreatic adenocarcinoma; PRAD—Prostate adenocarcinoma; PCPG—Pheochromocytoma and Paraganglioma; READ—Rectum adenocacinoma; SARC—Sarcoma; SKCM—Skin cutaneous melanoma; LAML—Acute Myeloid Leukemia; TGCT—Testis germ cell tumors; THCA—Thyroid carcinoma; THYM—Thymoma; STAD—Stomach adenocarcinomna; UCEC—Uterine corpus endometrial carcinoma; USC—Uterine carcinosarcoma; UVM—Uveal Melanoma.